This preprint is under consideration at Scientific Reports. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research Article
Network Pharmacology-Based Investigation of Potential Targets of Astragalus-Angelica Compound Acting on Diabetic Nephropathy
Quanlin Zhao
Affiliated Hospital of Shandong University of Traditional Chinese Medicine
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Through network pharmacology and molecular docking to explore the mechanism of astragalus-angelica compound in the treatment of diabetic nephropathy (DN). Screen the components and targets of astragalus and angelica compound on the TCMSP and the BATMAN-TCM, and use Cytoscape 3.7.2 to establish a component-target interaction network. Relevant targets of DN were searched through related databases, and the common targets of astragalus-angelica compound prescription and DN were obtained after comparison. The target protein interaction analysis and visualization processing were performed, and gene ontology (GO) analysis and Kyoto Encyclopedia of Gene and Genome (KEGG) pathway enrichment analysis were performed through David database, and molecular docking was performed using PyMoL and AutoDock Vina software. Through network pharmacology screening, 142 main targets of astragalus-angelica compound in the treatment of DN have been identified. KEGG pathway enrichment analysis shows that the above key targets are related to apoptosis, oxidative stress, inflammation, insulin resistance and other related pathways. Molecular docking shows that the target protein has a good combination with the main active ingredients of astragalus-angelica compound. Astragalus-angelica compound may act on VEGFA, TP53, IL-6, TNF, mark1 and other targets to treat DN by regulating apoptosis, oxidative stress, inflammation, glucose and lipid metabolism and other pathways. Research methods based on network pharmacology and molecular docking provide new ideas for the pathogenesis and treatment of DN.
Keywords
network pharmacology, astragalus-angelica compound, diabetic nephropathy, molecular docking
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 11 Jan, 2021
No community comments so far
Editor invited
On 07 Jan, 2021
Submission checks complete
On 07 Jan, 2021
First submitted
On 07 Jan, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
This preprint is under consideration at Scientific Reports. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research Article
Network Pharmacology-Based Investigation of Potential Targets of Astragalus-Angelica Compound Acting on Diabetic Nephropathy
Quanlin Zhao
Affiliated Hospital of Shandong University of Traditional Chinese Medicine
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 11 Jan, 2021
No community comments so far
Editor invited
On 07 Jan, 2021
Submission checks complete
On 07 Jan, 2021
First submitted
On 07 Jan, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Through network pharmacology and molecular docking to explore the mechanism of astragalus-angelica compound in the treatment of diabetic nephropathy (DN). Screen the components and targets of astragalus and angelica compound on the TCMSP and the BATMAN-TCM, and use Cytoscape 3.7.2 to establish a component-target interaction network. Relevant targets of DN were searched through related databases, and the common targets of astragalus-angelica compound prescription and DN were obtained after comparison. The target protein interaction analysis and visualization processing were performed, and gene ontology (GO) analysis and Kyoto Encyclopedia of Gene and Genome (KEGG) pathway enrichment analysis were performed through David database, and molecular docking was performed using PyMoL and AutoDock Vina software. Through network pharmacology screening, 142 main targets of astragalus-angelica compound in the treatment of DN have been identified. KEGG pathway enrichment analysis shows that the above key targets are related to apoptosis, oxidative stress, inflammation, insulin resistance and other related pathways. Molecular docking shows that the target protein has a good combination with the main active ingredients of astragalus-angelica compound. Astragalus-angelica compound may act on VEGFA, TP53, IL-6, TNF, mark1 and other targets to treat DN by regulating apoptosis, oxidative stress, inflammation, glucose and lipid metabolism and other pathways. Research methods based on network pharmacology and molecular docking provide new ideas for the pathogenesis and treatment of DN.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9